The problem is that when others criticize based on what THEY themselves are willing to risk. That’s nobody’s decision but theirs. I wish I had more shares. I only have 2700. But that’s more than some others too. The point is that we all see the value behind this company’s drug, regardless of how many shares.
But to insinuate that the risk is ‘too high’ when we have all these catalysts and expected catalysts in the wake of superb cancer data? To me, that is absurd. It would be different if we were still mid way of phase I. We are well beyond that, and the data backs this drug up.
Can’t wait to see what the end of the year holds. Good luck, JustAguy. You’ve got a lot of people envious at the number of shares you hold. ;-)
News 
Market Data 
Discover 
